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Abstract Sarcopenia, lowmuscle mass, is an increasing
problem in our ageing society. The prevalence of sarco-
penia varies extremely between elderly cohorts ranging
from 7% to over 50%. Without consensus on the defini-
tion of sarcopenia, a variety of diagnostic criteria are
being used. We assessed the degree of agreement be-
tween seven different diagnostic criteria for sarcopenia
based on muscle mass and handgrip strength, described
in literature. In this cross-sectional study, we included
men (n0325) and women (n0329) with complete meas-
urements of handgrip strength and body composition
values as measured by bioimpedance analysis within
the Leiden Longevity Study. Prevalence of sarcopenia
was stratified by gender and age. In men (mean age
64.5 years), the prevalence of sarcopenia with the differ-
ent diagnostic criteria ranged from 0% to 20.8% in the
lowest age category (below 60 years), from 0% to 31.2%
in the middle (60 to 69 years) and from 0% to 45.2% in
the highest age category (above 70 years). In women
(mean age 61.8 years), the prevalence of sarcopenia
ranged from 0% to 15.6%, 0% to 21.8% and 0% to
25.8% in the lowest, middle and highest age category,
respectively. Only one participant (0.2%) was identified
having sarcopenia according to all diagnostic criteria that
marked prevalence above 0%. We conclude that the
prevalence of sarcopenia is highly dependent on the
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applied diagnostic criteria. It is necessary to reach a
consensus on the definition of sarcopenia in order to
make studies comparable and for implementation in
clinical care.
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Introduction
Sarcopenia, low muscle mass at older age, is an increas-
ing problem in our ageing society. Annual loss of mus-
cle mass has been reported as 1% to 2% at the age of
50 years onwards (Buford et al. 2010; Marcell 2003),
and it exceeds over 50% among those aged 80 years and
older when compared to younger adults (Baumgartner et
al. 1998). The change of muscle mass is closely related
to changes in muscle strength. Reduced muscle strength
has been found to be associated with dependency in
activities of daily living (Rantanen et al. 2002; Taekema
et al. 2010), cognitive decline (Alfaro-Acha et al. 2006;
Burns et al. 2010; Taekema et al. 2011) and mortality
(Ling et al. 2010; Cooper et al. 2010). Next to the
generation of muscle strength, muscle tissue is an im-
portant reserve of body proteins and energy that can be
used in extreme conditions of stress or malnutrition.
Lowmuscle mass is associated with higher drug toxicity
(Morgan and Bray 1994; Nawaratne et al. 1998) and
reduced insulin sensitivity (Kalyani et al. 2012).
Since the coining of the term ‘sarcopenia’ in 1989
by Rosenberg (Rosenberg 1997), many suggestions
have been made to try to establish a clinically appli-
cable definition. In general, three possible approaches
in defining sarcopenia have been suggested. Accord-
ing to the first, the amount of muscle mass, measured
with dual-energy X-ray absorptiometry (DXA) or bio-
impedance analysis (BIA), compared to a younger
reference population determines whether a person
has sarcopenia. Correction factors applied using this
approach are height (Baumgartner et al. 1998; Janssen
et al. 2004), body mass (Janssen et al. 2002), or both
body height and body fat (Newman et al. 2003). In the
second approach, muscle function is used as diagnos-
tic criterion to define sarcopenia as compared to a
younger reference population (Lauretani et al. 2003).
The third approach combines both muscle mass and
muscle function in the definition (Cruz-Jentoft et al.
2010; Muscaritoli et al. 2010).
Little is known about the degree of agreement
between the diagnostic criteria and their effects on
estimates of the prevalence of sarcopenia, which
appears to vary extremely between different cohorts
ranging from 7% to over 50% in the elderly (Abellan
van Kan 2009; Baumgartner et al. 1998; Janssen et al.
2002; Lauretani et al. 2003; Newman et al. 2003). The
use of different diagnostic criteria may lead to differ-
ent conclusions and may have different implications
for treatment. To the best of our knowledge, the differ-
ences in prevalence of sarcopenia in middle aged
people comparing different diagnostic criteria have
not been previously reported. In the present paper, we
explore the prevalence of sarcopenia using seven differ-
ent diagnostic criteria in a large cohort of Dutch middle
aged people. Furthermore, we assess the degree of con-
cordance within individuals using the different criteria.
Therewith, we aim to show the importance of reaching a
consensus on the definition of sarcopenia, for clinical
research and patient care.
Methods
Study cohort
The Leiden Longevity Study (LLS) consists of long-
living Caucasian siblings of 420 families together with
their middle aged offspring, and the partners of the
offspring as controls (Schoenmaker et al. 2006). The
study included 674 participants of the middle aged to
older offspring and their partners, who were assessed in
the period from 2006 to 2008. The sample of partners in
the study was representative of the Dutch population
(Schoenmaker et al. 2006). Participants (n020) with
missing data for body composition measured with Direct
Segmental Multi-frequency Bioelectrical Impedance
Analysis (DSM-BIA) were excluded from the present
analysis. There were no selection criteria on health or
demographic characteristics (Westendorp et al. 2009).
The Medical Ethics Committee of the Leiden University
Medical Centre approved the study, and written in-
formed consent was obtained from all participants.
Participant characteristics
At baseline, information on common chronic diseases
and medication use was obtained from the partici-
pants’ general practitioner, pharmacist’s records and
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from blood sample analyses. The chronic diseases
recorded were diabetes mellitus, chronic obstructive
pulmonary disease, malignancy, myocardial infarction,
stroke and hypertension. Health behaviour variables
included current smoking status and excessive alcohol
use (male >210 g/week and female >140 g/week).
Body composition
Body mass and body height were measured. DSM-
BIA was performed using the In-Body (720) body
composition analyser (Biospace Co., Ltd, Seoul,
Korea). We have previously shown this technique
to be a valid tool for the assessment of whole
body composition and segmental lean mass meas-
urements in our sample of a middle aged people
(Ling et al. 2011a). Excellent agreements were
observed between the DSM-BIA technique and
DXA in whole body lean mass [intraclass correla-
tion coefficient (ICC) female00.95, p<0.001; ICC
male00.96, p<0.001] and fat mass (ICC female0
0.97, p<0.001; ICC male00.93, p<0.001) (Ling et
al. 2011a). The DSM-BIA technique is based on
the assumption that the human body is composed
of five interconnecting cylinders and takes direct
impedance measurements from the various body
compartments. A tetrapolar eight point tactile elec-
trode system is used, which separately measures
impedance of the participant’s trunk, arms and legs
at six different frequencies (1 kHz, 5 kHz, 50 kHz,
250 kHz, 500 kHz, and 1,000 kHz) for each of the
body segments. The spectrum of electrical frequencies
is used to predict the intracellular water (ICW) and
extracellular water (ECW) compartments of the total
body water (TBW) in the various body segments. Lean
body mass is estimated as TBW (ICW+ECW)/0.73.
Body fat mass is calculated as the difference between
total body mass and lean mass. The machine gives
immediate detailed results including quantitative values
of total body and segmental lean mass, fat mass and
percentage fat mass. Appendicular lean mass (ALM)
calculation was based on the sum of lean mass in all
four limbs. Relative ALM was calculated as ALM di-
vided by body height in meters squared (Baumgartner et
al. 1998). Participants wore normal indoor clothing and
were asked to stand barefoot on the machine platform
with their arms abducted and hands gripping on to the
handle of the machine.
Handgrip strength
Handgrip strength was measured to the nearest kilogram
using a Jamar hand dynamometer (Sammons Preston,
Inc., Bolingbrook, IL, USA). All participants were
instructed to maintain an upright standing position, arms
down by the side, and holding the dynamometer in the
dominant hand without squeezing the arm against the
body. The width of the dynamometer’s handle was
adjusted to the hand size of the participants such that
the middle phalanx rested on the inner handle. Partic-
ipants were allowed to perform one test trial, followed
by three trials, and the best measurement was taken for
analysis.
Diagnostic criteria of sarcopenia
An overview of widely used different diagnostic cri-
teria of sarcopenia (coded A to G), which included
muscle mass and handgrip strength, is given in Table 1
(Baumgartner et al. 1998; Delmonico et al. 2007;
Janssen et al. 2002, 2004; Lauretani et al. 2003). Only
diagnostic criteria based on measurements of muscle
mass by BIA (definition E and F) or DXA (definition
A, B, C and D) scanning were used in this comparison.
This overview is not a complete representation of all
diagnostic criteria that have been described in the
literature, for example cut-off points derived from
Chinese populations are not shown (Lau et al. 2005;
Woo et al. 2009). For each of the formulas described
in Table 1, a different reference population had been
used to derive a cut-off point for sarcopenia. For the
formula ALM divided by height squared (definition A,
B and C), we found three different cut-off points for
men and women, established in different reference
populations (Baumgartner et al. 1998; Delmonico et
al. 2007; Kelly et al. 2009). Reference populations
were different in age and ethnicity, consisting of youn-
ger participants of the Rosetta study (definition A)
(Baumgartner et al. 1998), the NHANES survey (def-
inition C) (Kelly et al. 2009) and the NHANES III
study (definition E) (Janssen et al. 2002); elderly par-
ticipants were included as reference population in the
Health ABC study (definition B) (Delmonico et al.
2007) and the NHANES III study (definition F) (Janssen
et al. 2004); the whole adult age range was included
in the reference population in the InCHIANTI study
(definition G) (Lauretani et al. 2003). The formula de-
scribed in definition D was applied to our cohort, using
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the 20th percentile as cut-off point for sarcopenia
(Delmonico et al. 2007). Consequently, we used a
total of seven different diagnostic criteria of sarcopenia
in our analysis.
Statistical analysis
Data were analysed for men and women separately.
Because there was no significant difference in fat per-
centage, relative ALM, and handgrip strength between
offspring and partners of the LLS, data for both groups
were combined (Ling et al. 2011b). The prevalence of
sarcopenia in this population was assessed for all seven
diagnostic criteria as described in Table 1. For definition
D, the residuals of linear regression of ALMwith height
and fat mass were calculated.
After assigning the status of sarcopenia being pres-
ent or not present in the participants according to each
of the seven diagnostic criteria, participants were strat-
ified by gender and age. The lowest age category
included participants aged below 60 years, the middle
age category included participants aged 60 to 69 years
and the highest included participants aged 70 years
and above. Differences between age groups in charac-
teristics were assessed with linear regression or binary
logistic regression. The degree of concordance within
individuals using the different diagnostic criteria of
sarcopenia was assessed in all participants. The differ-
ence in participant characteristics dependent on the
diagnostic criterion was tested using Student’s t-test.
All statistical analyses were performed using SPSS
forWindows (SPSS Inc., Chicago, IL, USA), version 17.
P values <0.05 were considered statistically significant.
Results
Baseline characteristics of the study participants strati-
fied by gender and age are presented in Table 2. Overall,
the prevalence of comorbidity was slightly higher in
older participants (statistically not significant). Skeletal
lean mass as a percentage of body mass and grip strength
were significantly lower in the older age groups. ALM
divided by height squared was significantly different
between the age groups in men, but not in women.
The prevalence of sarcopenia using the seven dif-
ferent diagnostic criteria is shown in Table 3. In men,
the prevalence ranged from 0% to 20.8% in the lowest
age category, from 0% to 31.2% in the middle age
category and from 0% to 45.2% in the highest age
category. In women, percentages ranged from 0% to
15.6%, 0% to 21.8% and 0% to 25.8% in the lowest,
middle and highest age category, respectively.
Definitions A, B and C are based on the same
formula taking height into account, but each com-
prised different reference populations and strategies
to define cut-off points. In men, prevalence varied
from 0% to 3.9% (lowest age category), 0% to 4.3%
(middle age category) and 0% to 6.5% (highest age
category). In women, this variation for definitions A,
B and C was 0% to 3.1% (lowest age category), 0% to
3.5% (middle age category) and 0% (highest age cat-
egory). When applying cut-off points for definition E
class II, two men (0.6%) and one woman (0.3%) were
classified as sarcopenic. The prevalence of sarcopenia
was higher when applying cut-off points for definition
E class I. Only one of the men (0.3%) was sarcopenic
according to definition F class II criteria, based on
muscle mass and height. The prevalence was higher
using definition F class I criteria. The use of definition
G, which included hand grip strength, gave a prevalence
of less than 4% in this middle aged cohort.
Figure 1 shows the distribution of participants iden-
tified as sarcopenic according to the different diagnos-
tic criteria. Definition C, which gave zero prevalence
of sarcopenia, is omitted. For definition E and F, class
I and class II sarcopenia are combined. Out of the 654
participants, 436 did not have sarcopenia according to
any definition. For 218 participants, the diagnosis of
sarcopenia depended on the diagnostic criteria applied.
Only one of the participants (0.2%) was sarcopenic
according to all six definitions.
Since the highest number of participants was sarco-
penic according to definition D (n0130) or F (n0104),
we analysed participant characteristics in these sub-
groups. We were mainly interested in the subgroups of
56 participants being sarcopenic only in definition D
and of 38 participants being sarcopenic only in defini-
tion F. While BMI was comparable in these subgroups
(in D 24.4 kg/m2 and in F 24.6 kg/m2), fat percentage
was significantly higher in definition D compared to F
(35.6% and 23.3%, respectively, p<0.001).
Discussion
In this large middle aged Dutch cohort, the prevalence
of sarcopenia varied widely depending on which
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diagnostic criteria were used. Criteria based on low
grip strength and skeletal lean mass failed to match
with criteria based on appendicular lean mass. There
was substantial overlap between diagnostic criteria A
and B which are both based on the amount of appen-
dicular lean mass, yet another cut-off point for the
amount of appendicular lean mass resulted in the ab-
sence of sarcopenia (diagnostic criterion C). These find-
ings clearly demonstrate the highly different selection of
participants with the diagnosis sarcopenia using various
criteria. Consequently, there are concerns about the va-
lidity of comparisons between studies using different
criteria to diagnose sarcopenia.
The question arises which properties of skeletal
muscle are represented by the term sarcopenia. Be-
sides the production of force, muscle tissue is also an
important regulator of biological processes. For in-
stance, as a protein store it provides a homeostatic
Table 2 Baseline characteristics of study participants, stratified for gender and age
Variablesa Men Women
Age (years) Age (years)
≤59 60–69 ≥70 P for
trend
≤59 60–69 ≥70 P for
trend
(n077) (n0186) (n062) (n0128) (n0170) (n031)
Age (years, mean, range) 56.1 (45–59) 64.9 (60–69) 73.5 (70–82) 55.6 (38–59) 64.5 (60–69) 72.3 (70–78)
Height (m) 1.81 (0.07) 1.78 (0.06) 1.76 (0.07) <0.001 1.67 (0.06) 1.66 (0.1) 1.64 (0.6) 0.02
Body mass (kg) 86.7 (11.0) 85.5 (11.8) 84.1 (10.1) 0.17 71.7 (12.5) 72.6 (13.1) 76.0 (11.4) 0.15
Body mass index (kg/m2) 26.6 (3.3) 27.0 (3.2) 27.2 (2.9) 0.25 25.8 (4.4) 26.4 (4.7) 28.2 (4.0) 0.01
Total body fat mass (%) 23.4 (6.1) 25.8 (5.9) 28.0 (7.1) <0.001 33.7 (7.5) 35.2 (7.1) 39.4 (6.7) <0.001
Skeletal lean mass (kg) 37.2 (4.1) 35.3 (4.0) 33.3 (3.9) <0.001 25.7 (3.3) 25.3 (3.3) 24.7 (3.0) 0.10
Skeletal lean mass (%)b 43.1 (3.5) 41.5 (3.4) 39.8 (4.0) <0.001 36.2 (4.1) 35.3 (3.9) 32.8 (3.8) <0.001
ALMc (kg) 28.0 (3.3) 26.7 (3.2) 25.5 (3.3) <0.001 19.3 (2.7) 18.9 (2.7) 18.9 (2.5) 0.31
Relative ALMd (kg/m2) 8.6 (0.6) 8.4 (0.6) 8.2 (0.6) 0.002 6.9 (0.7) 6.9 (0.8) 7.0 (0.7) 0.78
Handgrip strength (kg) 51.1 (7.9) 46.8 (7.2) 41.7 (8.1) <0.001 31.1 (6.4) 29.0 (5.0) 26.6 (4.8) <0.001
Comorbidities (n %)
Myocardial infarction 1 (1.3) 8 (4.3) 3 (4.8) 0.25 0 1 (0.6) 1 (3.2) 0.11
Stroke 1 (1.3) 5 (2.7) 5 (8.1) 0.04 2 (1.6) 3 (1.8) 0 0.70
Hypertension 10 (13.0) 50 (26.9) 20 (32.3) 0.006 25 (19.5) 47 (27.6) 13 (41.9) 0.008
Diabetes mellitus 5 (6.5) 16 (8.6) 6 (9.7) 0.48 6 (4.7) 7 (4.1) 4 (12.9) 0.25
Neoplasm 2 (2.6) 12 (6.5) 6 (9.7) 0.08 6 (4.7) 14 (8.2) 3 (9.7) 0.18
Chronic obstructive
pulmonary disease
3 (3.9) 7 (3.8) 5 (8.1) 0.26 5 (3.9) 3 (1.8) 2 (6.5) 0.99
Rheumatoid arthritis 1 (1.3) 1 (0.5) 1 (1.6) 0.90 1 (0.8) 2 (1.2) 0 0.91
Sum score of medicatione,
median (IQR)
0 (0–0) 0 (0–1) 0 (0–1) <0.001 0 (0–1) 0 (0–1) 0 (0–2) 0.02
Current smoking (n %) 10 (13.0) 24 (12.9) 6 (9.7) 0.61 21 (16.4) 16 (9.4) 1 (3.2) 0.02
Excessive alcohol usef
(n %)
20 (26.0) 57 (30.6) 14 (22.6) 0.95 19 (14.8) 24 (14.1) 5 (16.1) 0.90
a Variables are presented in mean, SD, unless indicated otherwise. P values for trend were calculated using linear or logistic regression
b Skeletal lean mass/total body mass·100%
cAppendicular lean mass, sum measurement of lean mass in all four limbs
d Appendicular lean mass adjusted for height (appendicular lean mass/height2 )
e Sum score of total number of oral medication, data available in males (n0272) and females (n0268)
fMale >210 g/week and female >140 g/week
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reserve to recover from disease (Englesbe et al.
2010). Furthermore, skeletal muscle has been iden-
tified as the major tissue involved in glucose me-
tabolism (Corcoran et al. 2007; Shulman et al. 1990).
Current evidence suggests that lean body mass may be a
better measure for normalising dosages of drugs that are
distributed and metabolised in lean tissue, compared
with body surface area alone (Morgan and Bray 1994;
Nawaratne et al. 1998; Prado et al. 2009). This under-
lines the importance to evaluate muscle mass in aging
subjects.
In the present study, there was little overlap be-
tween individuals with low grip strength and low
muscle mass using the diagnostic criteria. A possible
explanation is that muscle strength is not only deter-
mined by muscle mass. The amount of muscle mass
represents the number of sarcomeres that are in paral-
lel. As each sarcomere is capable of exerting an
amount of force, the number of sarcomeres in parallel,
together with the quality of proteins and connective
tissue determines the amount of force that a muscle
can potentially exert. Additionally, muscle function is
Table 3 Prevalence of sarcopenia (n %) in the middle aged study population stratified by gender and age
Codea Men Women
Age (years) Total Age (years) Total
≤59 60–69 ≥70 ≤59 60–69 ≥70
(n077) (n0186) (n062) (n0325) (n0128) (n0170) (n031) (n0329)
A 3 (3.9) 8 (4.3) 4 (6.5) 15 (4.6) 2 (1.6) 5 (2.9) 0 7 (2.1)
B 3 (3.9) 8 (4.3) 4 (6.5) 15 (4.6) 4 (3.1) 6 (3.5) 0 10 (3.0)
C 0 0 0 0 0 0 0 0
D 12 (15.6) 35 (18.8) 18 (29.0) 65 (20.0) 20 (15.6) 37 (21.8) 8 (25.8) 65 (19.8)
E1 3 (3.9) 17 (9.1) 16 (25.8) 36 (11.1) 4 (3.1) 8 (4.7) 4 (12.9) 16 (4.9)
E2 1 (1.3) 0 1 (1.6) 2 (0.6) 0 0 1 (3.2) 1 (0.3)
F1 16 (20.8) 58 (31.2) 28 (45.2) 102 (31.4) 0 0 1 (3.2) 1 (0.3)
F2 0 0 1 (1.6) 1 (0.3) 0 0 0 0
G 1 (1.3) 2 (1.1) 5 (8.1) 8 (2.5) 3 (2.3) 6 (3.5) 0 9 (2.7)
a The letters represent codes for the applied definition. The code is fully described in Table 1
Fig. 1 Number of partici-
pants identified as having
sarcopenia according to vari-
ous definitions, represented
by letter codes. A description
of the codes can be found in
Table 1. A total of 654 were
evaluated. Definition C, in
which no participants were
sarcopenic, is not shown. In
definition E and F, class I and
II sarcopenia are combined.
Two subjects, one in whom
sarcopenia was diagnosed
according to F, G and E, and
one in whom sarcopenia
was diagnosed according to
B and D, are not shown in
the figure
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dictated by energy supply and neural control. Conse-
quently, the terms muscle mass and muscle strength
cannot be used interchangeably (Clark and Manini
2008). The rate of decline in muscle strength at older
age appears to be higher than the decline in muscle
mass in a 3-year longitudinal study, suggesting that
factors other than muscle mass are influential
(Goodpaster et al. 2006). Additionally, the increase
of strength after resistance training is higher than
the increase in muscle mass in older adults (Fiatarone
et al. 1994; Kemmler et al. 2010; Orsatti et al. 2008;
Sillanpaa et al. 2009). In a recent meta-analysis, it was
shown that handgrip strength decreases each year with
0.37 kg (95% CI 0.31–0.44) after 50 years of age
(Beenakker et al. 2010). Still, the low prevalence
of sarcopenia in our cohort based on cut-off points
for handgrip strength can possibly be explained by
the fact that our cohort was middle aged and not
over 80 years of age, where lower muscle strength
becomes even more apparent (McNeil et al. 2005).
Recently, a new term, dynapenia, has been developed
to describe low muscle strength at old age (Clark and
Manini 2008). The use of the terms dynapenia for low
muscle strength, and sarcopenia for low muscle mass,
emphasises the differences between muscle strength and
mass. However, this terminology might overcomplicate
the situation unnecessarily since muscle mass is also
needed to generate strength. In other words, low muscle
strength is one of the possible consequences of low
muscle mass.
The prevalence of sarcopenia determined by diag-
nostic criteria using ALM corrected for height was not
related to chronological age in women. However, the
total lean mass as a percentage of total body mass was
lower in all older subjects. This provides evidence that
the interpretation of the amount of muscle mass is
highly dependent on applied correction factors, such
as fat mass and height. This is supported by the sub-
group analysis of participants who were only sarco-
penic in diagnostic criterium D, who had a high fat
percentage and a relatively low muscle mass that was
not recognised in diagnostic criteria adjusting for
height only. Newman et al. found that correction for
height only could lead to an overestimation of sarco-
penia in underweight individuals, compared to an
underestimation of sarcopenia in obese individuals
(Newman et al. 2003). Furthermore, recent studies
suggest that high fat mass is an important and inde-
pendent determinant of functional status in elderly,
even after adjustment for the level of physical activity
(Lebrun et al. 2006; Rolland et al. 2009; Visser et al.
1998, 2005).
Next to a valid assessment of the amount of muscle
mass, some variability emerges from the comparison
to different reference populations and different cut-off
points. Even with this variability, the degree of agree-
ment between diagnostic criteria with the same formu-
la but different cut-off points (definition A and B) was
substantial. The prevalence of sarcopenia of zero per-
cent using definition C can be explained by differ-
ences in reference populations. Furthermore, the
prevalence of sarcopenia with definition A in this
study cohort was much lower than reported in the
same age categories by Baumgartner et al. (1998). In
that study, using the same cut-off points in non-
Hispanic whites, the prevalence of sarcopenia was
found to be 13.5–23.1% below 70 years, and 19.8–
33.3% between 70 and 74 years, in men and women,
respectively. Differences in reference groups may be
caused by age, ethnicity, genetic background and en-
vironmental factors such as the level of physical ac-
tivity. Therefore, it is important to agree on reference
populations that can be used in specific ethnic groups.
Establishing reference databases generally requires a
large sample size to achieve reliable results. Reference
databases established to diagnose osteoporosis could
function as a role model. Furthermore, it remains
important to invest in longitudinal studies including
the general population assessing the relation between
muscle mass and functional outcomes to establish
possible critical thresholds of muscle mass needed for
muscle function.
Until now, attempts to approve on a consensus
definition for sarcopenia failed. To the best of our
knowledge, three international consortia have agreed
on distinct definitions, which have not been generally
accepted in the medical community. The first consen-
sus definition was published by the Special Interest
Groups (SIG) in 2009 (Muscaritoli et al. 2010). Here,
the diagnosis sarcopenia is based on a combination of
low muscle mass as defined by Janssen in 2002 (def-
inition E) (Janssen et al. 2002), together with low gait
speed, which is walking speed below 0.8 m/s in the
4-m walking test, or another functional test (Muscaritoli
et al. 2010). The second consensus definition was pub-
lished by The European Working Group on Sarcopenia
in Older People (EWGSOP) in 2010. The EWGSOP
included a degree of severity of sarcopenia in the
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definition. ‘Presarcopenia’ was defined as low muscle
mass, ‘sarcopenia’ as low muscle mass together with
either low muscle strength or performance and ‘severe
sarcopenia’ as a combination of all three. In addition, it
was proposed that sarcopenia should be considered ‘pri-
mary’ when no other cause is evident but ageing itself,
and ‘secondary’ when one or more other causes are
evident (Cruz-Jentoft et al. 2010). This terminology is
not acceptable in modern gerontology, as age in itself is
no longer considered a causal factor of disease (Holliday
1999). In the third consensus definition, Fielding et al.
based the diagnosis of sarcopenia on lowmuscle mass as
defined by Delmonico et al. (definition B) (Delmonico et
al. 2007), together with low gait speed defined as less
than 1 m/s (Fielding et al. 2011).
In our opinion, these consensus definitions are not
clinically applicable. First of all, using the SIG defini-
tion, none of the participants in the present study
fulfilled the criteria for low muscle mass. Furthermore,
gait speed is not a parameter of muscle function alone,
but also dependent on other factors such as cognition,
neural control, joint function and cardiovascular fit-
ness (Hajjar et al. 2011). The EWGSOP definition lists
different ways to diagnose sarcopenia, without making
a choice which measurement should be used. Conse-
quently, the huge variability of prevalence of sarcope-
nia highlighted in the present study would therefore
still be present. It is important to keep the differences
between diagnostic criteria in consideration when
interpreting the results of studies where muscle tissue
is evaluated.
The strength of the present study is that the current-
ly used diagnostic criteria of sarcopenia were applied
to one study population. There are some limitations to
the use of DXA since different densitometers and
software versions have been shown to give different
estimates of body composition (Paton et al. 1995;
Tataranni et al. 1996). The use of different equations
between various BIA machines could also contribute
to different body composition parameters. Abnormal
hydration status or extreme body weight might also
influence the measurements (Woodrow 2009). Previ-
ously, we have shown an excellent correlation between
BIA and DXA measurements (Ling et al. 2011a); there-
fore, we were able to apply diagnostic criteria based on
both DXA and BIA measurements. A possible limita-
tion of this study is selection bias of the participants
since only the partners of the offspring of nonagenarian
siblings are considered to be representatives of the
general population. However, the offspring of long-
lived families did not differ significantly from their
partners in fat percentage, muscle mass and handgrip
strength (Ling et al. 2011b). Therefore, this would not
influence conclusions made in the present study. More-
over, participants weremiddle aged; the degree of agree-
ment between the different diagnostic criteria for
sarcopenia might be different in an oldest old popula-
tion. Another limitation is that we had no functional
outcome measures available for participants in this
study. We were not able to apply diagnostic criteria for
sarcopenia based on gait speed.
In conclusion, the prevalence of sarcopenia varies
widely depending on the applied diagnostic criteria. A
consensus definition is necessary in order to make
studies comparable and for implementation in clinical
care. Until there is universal consensus, the diagnostic
criteria used to define sarcopenia in separate studies
should be clearly described, without the interchangeable
use of the terms muscle mass and muscle strength.
Further research should focus on establishing an appro-
priate formula to correct the amount of muscle mass for
factors such as height and fat mass, and take into ac-
count differences in ethnicity when subjects are com-
pared to reference populations.
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